Literature DB >> 11147577

The clinical value of serum S-100 protein measurements in minor head injury: a Scandinavian multicentre study.

T Ingebrigtsen1, B Romner, S Marup-Jensen, M Dons, C Lundqvist, J Bellner, C Alling, S E Børgesen.   

Abstract

PURPOSE: This study of patients with minor head injury was designed to investigate the relation of S-100 protein measurements to computed tomograpy (CT) findings and patients outcomes. Increased serum levels of this protein were hypothetized to predict intracranial pathology and increased frequency of post-concussion symptoms.
METHODS: One hundred and eighty-two patients were studied with Glasgow Coma Scale scores of 13-15. The study recruited patients from three Scandinavian neurotrauma centres. Serum levels of S-100 protein were measured at admittance and CT scans of the brain were obtained within 24 hours postinjury in all patients. Outcome was evaluated with the Rivermead Postconcussion Symptoms Questionnaire (RPQ) 3 months after the injury.
RESULTS: Increased serum level of S-100 protein was detected in 69 (38%) patients, and CT scan demonstrated intracranial pathology in 10 (5%) (brain contusion in seven, epidural haematoma in two, traumatic subarachnoid haemorrhage in one). The proportion of patients with detectable serum level was significantly (p < 0.01) higher among those with intracranial pathology (90%) compared to those without (35%). The negative predictive value of an undetectable S-100 level was 0.99. Sixty-two per cent reported one or more post-concussion symptoms at follow-up. A trend was observed towards an increased frequency of post-concussion symptoms among patients with detectable serum levels.
CONCLUSIONS: Undetectable serum level of S-100 protein predicts normal intracranial findings on CT scan. Determination of S-100 protein in serum may be used to select patients for CT scanning. Increased S-100 serum levels may be more related to post-concussion symptoms caused by mild traumatic brain injury than to symptoms of psychological origin.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11147577     DOI: 10.1080/02699050050203540

Source DB:  PubMed          Journal:  Brain Inj        ISSN: 0269-9052            Impact factor:   2.311


  28 in total

Review 1.  [Neuromonitoring with S-100 protein in the intensive care unit].

Authors:  M Fries; J Bickenbach; S Beckers; D Henzler; R Rossaint; R Kuhlen
Journal:  Anaesthesist       Date:  2004-10       Impact factor: 1.041

2.  TD-11 workshop report: characterization of monoclonal antibodies to S100 proteins.

Authors:  Elisabeth Paus; Mads Haugland Haugen; Kari Hauge Olsen; Kjersti Flatmark; Gunhild Mari Maelandsmo; Olle Nilsson; Eva Röijer; Maria Lundin; Christian Fermér; Maria Samsonova; Yuri Lebedin; Torgny Stigbrand
Journal:  Tumour Biol       Date:  2010-07-24

3.  Diagnostic value of Elecsys S100 as a marker of acute brain injury in the emergency department.

Authors:  Eun-Jee Oh; Young-Min Kim; Dong-Wook Jegal; Jimin Kahng; Yeon-Joon Park; Kyungja Han
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

Review 4.  Current status of fluid biomarkers in mild traumatic brain injury.

Authors:  Jacqueline R Kulbe; James W Geddes
Journal:  Exp Neurol       Date:  2015-05-14       Impact factor: 5.330

5.  [Serological determination of protein S100B. Significance in emergency diagnosis of adults with mild craniocerebral trauma--meta-analysis].

Authors:  B A Leidel; V Bogner; M Zock; K-G Kanz
Journal:  Unfallchirurg       Date:  2012-10       Impact factor: 1.000

6.  GFAP out-performs S100β in detecting traumatic intracranial lesions on computed tomography in trauma patients with mild traumatic brain injury and those with extracranial lesions.

Authors:  Linda Papa; Salvatore Silvestri; Gretchen M Brophy; Philip Giordano; Jay L Falk; Carolina F Braga; Ciara N Tan; Neema J Ameli; Jason A Demery; Neha K Dixit; Matthew E Mendes; Ronald L Hayes; Kevin K W Wang; Claudia S Robertson
Journal:  J Neurotrauma       Date:  2014-09-12       Impact factor: 5.269

7.  Inability of S100B to predict postconcussion syndrome in children who present to the emergency department with mild traumatic brain injury: a brief report.

Authors:  Lynn Babcock; Terri Byczkowski; Shari L Wade; Mona Ho; Jeffrey J Bazarian
Journal:  Pediatr Emerg Care       Date:  2013-04       Impact factor: 1.454

8.  Explorative investigation of biomarkers of brain damage and coagulation system activation in clinical stroke differentiation.

Authors:  Johan Undén; Karin Strandberg; Jan Malm; Eric Campbell; Lars Rosengren; Johan Stenflo; Bo Norrving; Bertil Romner; Arne Lindgren; Gunnar Andsberg
Journal:  J Neurol       Date:  2009-02-09       Impact factor: 4.849

9.  Serum S100beta: a noninvasive marker of blood-brain barrier function and brain lesions.

Authors:  Andrew A Kanner; Nicola Marchi; Vincent Fazio; Marc R Mayberg; Michael T Koltz; Vitaly Siomin; Glen H J Stevens; Thomas Masaryk; Barbara Aumayr; Barbara Ayumar; Michael A Vogelbaum; Gene H Barnett; Damir Janigro
Journal:  Cancer       Date:  2003-06-01       Impact factor: 6.860

10.  Biomarkers in the clinical diagnosis and management of traumatic brain injury.

Authors:  Georgene W Hergenroeder; John B Redell; Anthony N Moore; Pramod K Dash
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.